Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Breaking news! Rosiglitazone and cardiovascular risk

Nature Reviews Cardiology volume 7, pages 670–672 (2010)Cite this article

Subjects

In the past 3 years, several studies have reignited the controversy regarding the cardiovascular risk associated with the use of rosiglitazone. Until a prospective, well-controlled, randomized clinical trial is performed to adjudicate the issue definitively, physicians should be free to exercise clinical judgment, and weigh the comparative risks and benefits of agents such as rosiglitazone on a case-by-case basis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Nissen, S. E. & Wolski, K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191–1201 (2010).

    Article  CAS  Google Scholar 

  2. Graham, D. J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411–418 (2010).

    Article  CAS  Google Scholar 

  3. McGuire, D. K. et al. Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function. Eur. Heart J. doi:10.1093/eurheartj/ehq228.

    Article  CAS  Google Scholar 

  4. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457–2471 (2007).

    Article  CAS  Google Scholar 

  5. Diamond, G. A., Bax, L. & Kaul, S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann. Intern. Med. 147, 578–581 (2007).

    Article  Google Scholar 

  6. FDA. FDA Briefing Document: Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee July 30, 2007. FDA [online], (2007).

  7. FDA. FDA adds boxed warning for heart-related risk to anti-diabetes drug Avandia. FDA [online], (2009).

  8. Rucker, G. & Schumacher, M. Simpson's paradox visualized: the example of the rosiglitazone meta-analysis. BMC Med. Res. Methodol. 8, 34 (2008).

    Article  Google Scholar 

  9. Friedrich, J. O., Adhikari, N. K. & Beyene, J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med. Res. Methodol. 7, 5–11 (2007).

    Article  Google Scholar 

  10. Dargie, H. J. et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J. Am. Coll. Cardiol. 49, 1696–1704 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, 90048, CA, USA

    Sanjay Kaul & George A. Diamond

Authors
  1. Sanjay Kaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George A. Diamond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjay Kaul.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaul, S., Diamond, G. Breaking news! Rosiglitazone and cardiovascular risk. Nat Rev Cardiol 7, 670–672 (2010). https://doi.org/10.1038/nrcardio.2010.160

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.160

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing